By: IPP Bureau
Last updated : February 26, 2022 10:12 am
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
Out of the 49 projects approved so far under PLI scheme for Bulk Drugs, 8 projects with investment of Rs. 335 crore and with an annual production capacity of 16,021 MT have been commissioned as on date.
The Bulk Drug plants that have already been commissioned include CDA, Para Amino Phenol, Atorvastatin, Sulfadiazine, Oxcarbazepine, Levofloxacin , Carbidopa and Levodopa.
Further, 12 projects with committed investment of Rs. 504 crore and having annual production capacity of 18,614 MT are in the advanced stage of completion for commercial production and expected to be completed by 31st March, 2022.
The Government of India announced the PLI Scheme for Bulk Drugs in March 2020 to attain self-reliance in the sector of identified critical drugs whereby 49 projects were approved for 33 critical APIs with a committed investment of Rs. 3,685 crore.
Union Minister for Chemical & Fertilizers Dr. Mansukh Mandaviya complimented the industry representatives for this achievement towards attaining the vision of the Prime Minister for self-reliance in critical drugs leading to ‘Atamanirbhar Bharat’.
He encouraged the industry to invest in the area of research and innovation for sustainable global competitiveness by allocating adequate resources.
Complementing the industries, Minister of State, Bhagwant Khuba requested to expedite the grounding of remaining projects and starting of the commercial productions.
Initially, the Project Management Agency of the Scheme, IFCI Limited, has presented the overview of the scheme and said that against the notified capacity of 44,000 MT of the eligible products, the Industries have committed the annual capacity of over 83,000 MT.
The Department officials also mentioned that a third round of applications are invited for the remaining 10 eligible products under the scheme, with the last date till 13th March 2022 and requested the Industries to apply to avail the benefits under the scheme.
The meeting was attended by the Secretary Pharmaceuticals and representatives from Centrient Pharmaceuticals India, Meghmani, Emmennar Pharma, Andhra Organics, Hetero Group, Sadhana Nitro Chem and Sreepathi Pharmaceuticals.